Sign in
Taking peopleNo phase

Studying immune cells around pituitary tumors to find useful markers

Examines immune features in pituitary tumors of adults, looking for markers and treatment targets.

Key facts

Who runs it
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
NET-TIME: Inflammatory Tumor Microenvironment in Pituitary Neoplasm
Status
Recruiting
People taking part
60 people, planned
Started
3 Jun 2023
Expected to end
31 Mar 2027
Type of study
Observational
Record updated
18 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a pituitary tumor (PitNET) who are due to have surgery to remove it. The study looks at immune cells and markers inside the tumor.

Age
Over 18 years of age (record lists 18 Years to 100 Years).
Sex
All sexes can join.
Disease stage
A pituitary tumor (PitNET) that needs surgical removal under current guidelines. The diagnosis must be confirmed by tissue study after surgery.
Earlier treatment
No medical (drug) therapy for the tumor before surgery. This includes no somatostatin analogs or dopamine agonists.

Main reasons for not taking part

  • Past treatment with somatostatin analogs or dopamine agonists before tumor removal
  • Radiotherapy to the head and neck region earlier than 10 years after removal of the pituitary adenoma
  • History of autoimmune diseases

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • indication as per clinical practice and in agreement to current guidelines for surgical removal of the PitNET0
  • patient naïve to medical therapy before surgical removal of PitNET
  • Diagnosis of PitNET confirmed through the study pathological/histological
  • over 18 years of age
  • acceptance of participation in the study, by signing an informed consent

Who cannot take part

  • History of medical therapy with analogs of somatostatin or dopamine agonist, previous the removal of the pituitary adenoma
  • history of radiotherapy of the head and neck region earlier than 10 years after resection of the adenoma pituitary
  • history of autoimmune diseases

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

This trial is currently available in Italy.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Over the past twenty years, a progressively increasing number of markers biochemical, clinical, imaging, histopathological or genetic have been suggested to attempt to predict aggression and therapeutic outcome, both in secretory PitNETs and in non-secretory PitNETs. In recent years, the microenvironment tumor (TEM) has been extensively studied in different malignancies, promoting the development of therapies target and immunotherapy with checkpoint inhibitors immune system (ICI). Data on TIME in PitNETs are scarce today and derive from studies conducted mainly on heterogeneous cases for type of PitNET. Therefore, the purpose of this research project is to investigate the TIME in PitNET, to identify immune biomarkers and new molecular pathways that can promote the use of ICI and target therapies in Aggressive PitNETs.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Inflammatory Tumor Microenvironment in Pituitary Neoplasm
Plain-language title
Studying immune cells around pituitary tumors to find useful markersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07594262, who can take part
Record updated
18 May 2026